KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Debt (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Total Debt for 7 consecutive years, with $9.0 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 17.58% to $9.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 billion through Dec 2025, up 17.58% year-over-year, with the annual reading at $9.0 billion for FY2025, 17.58% up from the prior year.
  • Total Debt hit $9.0 billion in Q4 2025 for Royalty Pharma, roughly flat from $8.9 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $9.0 billion in Q4 2025 to a low of $5.9 billion in Q1 2021.
  • Historically, Total Debt has averaged $7.2 billion across 5 years, with a median of $7.2 billion in 2021.
  • Biggest five-year swings in Total Debt: decreased 13.8% in 2023 and later rose 24.08% in 2024.
  • Year by year, Total Debt stood at $7.2 billion in 2021, then dropped by 1.22% to $7.1 billion in 2022, then fell by 13.79% to $6.1 billion in 2023, then grew by 24.08% to $7.6 billion in 2024, then increased by 17.58% to $9.0 billion in 2025.
  • Business Quant data shows Total Debt for RPRX at $9.0 billion in Q4 2025, $8.9 billion in Q3 2025, and $8.0 billion in Q2 2025.